Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.
Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers.